If you happen to experience any new symptoms suggestive of your disease, you need to consult your doctor as soon as possible
The agency also notes possible risks related to immune reactions, peptide-related impurities, and difficulties in fully characterizing the active pharmaceutical ingredient
Consequently, agents that target the IL-1 pathway, such as anakinra (an IL-1 receptor antagonist) and canakinumab (a human anti-IL-1 monoclonal antibody), were investigated as potential treatment for SAH
Note: If you experience severe redness, warmth, or swelling at the injection site that lasts more than 48 hours, contact a healthcare professional immediately
These can include redness at the injection site, mild nausea, or a feeling of warmth